Drug Trial Radar · NCT02670161
Quality Improvement and Practice Based Research in Neurology Using the EMR
Last checked: Nov 19, 2026Latest source record: Aug 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
3,300
Planned (sponsor's estimate)
Start
May 2016
Primary completion
Dec 2026
Study completion Dec 2027
Sponsor
- Lead sponsor
- Endeavor HealthAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 1, 2016
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The investigators will conduct at NorthShore University HealthSystem pragmatic trials using the EMR for 10 common neurological disorders. They will demonstrate the feasibility of subgroup based adaptive assignment of treatments, electronic consenting, and outcomes data capture at the point of care using the EMR. They will identify the most effective treatments for common neurological disorders and seek replication by the NPBRN.
Conditions
- Brain Tumors
- Epilepsy
- Migraine
- Mild Cognitive Impairment
- Concussion
- Multiple Sclerosis
- Neuropathy
- Parkinson's
- Restless Legs Syndrome
- Stroke
Interventions
Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)Drug
brain tumors (lamotrigine, levetiracetam, valproic acid), epilepsy (lamotrigine, levetiracetam, valproic acid), mild cognitive impairment (donepezil, rivastigmine, memantine), migraine (amitriptyline, propranolol, topiramate), migraine (sumatriptan, rizatriptan, zolmitriptan), mild traumatic brain injury (omega-3 fatty acids, education only), multiple sclerosis (ACTH, methylprednisolone), neuropathy (duloxetine, pregabalin, amitryptiline), Parkinson's disease (pramipexole, ropinerole, rotigotine), restless legs syndrome (pramipexole, ropinerole, rotigotine), stroke (aspirin, clopidogrel).
Primary outcomes
What the sponsor says the trial is designed to measure.
- survival free of discontinuation or alternative prevention drug (migraine trial)Time frame: six months
- survival free of disability measured by FAQ score 9+ (memory trial)Time frame: one year
- survival free of discontinuation or alternative anti epileptic drug (epilepsy trial)Time frame: one year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
NorthShore University HealthSystem
Evanston, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.